

digitalhealth

REWired

BIRMINGHAM 12-13 MARCH 2024

Headline Sponsors:



ZOË BLAKE

CEO,
CARELOOP HEALTH



**PATIENT
ENGAGEMENT
STAGE**


Stage Sponsor:



PATIENTS KNOW BEST®
THE PATIENT'S COMPANY

A DTx for Psychosis & Schizophrenia

Supporting Self-Management
Predicting & Preventing Relapse




Psychosis & Schizophrenia in the UK

- 1% of the population will experience psychosis
- 80% will relapse within 5 years
- Average life expectancy 15 to 20 years less than general population
- Highest prevalence in most deprived inner-city areas & minority ethnic groups
- Far more likely to be unemployed, at risk of self harm and suicidal behaviour
- 220,000 receiving treatment today
- Schizophrenia care takes 30% of adult MH spend, and 75% of MH inpatient beds
- Around 4% of the total NHS budget (~£4bn)
- Current care models don't monitor for early signs of relapse which typically last 3-10 days



Active Symptom Monitoring



Early Warning Signals



Remote Monitoring



Our Journey to becoming a DTx

Developed in the NHS. Co-designed at every stage. 10+ years of research. 5 gold standard RCTs

"...CareLoop may enable earlier treatment, which could reduce hospitalisations and demand on crisis intervention services"

NICE EVA, Final guidance due 27 March 2024



50% fewer relapse episodes

15wks longer to first relapse



Patients less fearful of relapse

High adherence - 75% for 12 months



Twice as likely to be managed in community settings

14.3% less health professional time



33% cost reduction for hospital admissions

ICER of £3,041



NOW & NEXT

w: careloop.health
e: zoe@careloop.health

